TAZIDIME Drug Patent Profile
Which patents cover Tazidime, and what generic alternatives are available?
Tazidime is a drug marketed by Lilly and is included in two NDAs.
The generic ingredient in TAZIDIME is ceftazidime. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tazidime
A generic version of TAZIDIME was approved as ceftazidime by ACS DOBFAR on November 20th, 1985.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TAZIDIME?
- What are the global sales for TAZIDIME?
- What is Average Wholesale Price for TAZIDIME?
Summary for TAZIDIME
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Patent Applications: | 6,040 |
| DailyMed Link: | TAZIDIME at DailyMed |
US Patents and Regulatory Information for TAZIDIME
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | TAZIDIME | ceftazidime | INJECTABLE;INJECTION | 062655-001 | Nov 20, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-002 | Jul 10, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lilly | TAZIDIME | ceftazidime | INJECTABLE;INJECTION | 062655-002 | Nov 20, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-001 | Jul 10, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
